Esthesioneuroblastoma

Olfactory Oddity - Nose's Neural Nuisance

• Rare, aggressive malignant tumor from olfactory neuroepithelium (neural crest origin) in the nasal vault.
• Primary sites: Cribriform plate, superior nasal septum, superior turbinates.
• AKA: Olfactory Neuroblastoma.
• Symptoms: Progressive unilateral nasal obstruction, recurrent epistaxis, anosmia/hyposmia.
  • Advanced: Proptosis, diplopia, headache, facial pain.
• 

⭐ Exhibits a characteristic bimodal age distribution, with peaks in the 2nd decade (10-20 yrs) and 6th decade (50-60 yrs).

Sniffle Signals - When Smells Go Wrong

• Unilateral nasal obstruction: Most common, often progressive.
• Epistaxis: Recurrent, sometimes profuse nosebleeds.
• Anosmia/Hyposmia (loss/↓ smell): Key early sign.
• Headache, facial pain/fullness: From tumor mass.
• Proptosis, diplopia, ↓ vision: With orbital extension.
• Cranial nerve palsies: With skull base invasion.
• Watery rhinorrhea (CSF leak): Indicates dural involvement.

⭐ Persistent unilateral nasal obstruction and/or epistaxis in an adult should raise suspicion for nasal malignancy, including esthesioneuroblastoma.

Picture Perfect - Pinpointing the Problem

Error: Failed to generate content for this concept group.

Battle Plan - Tackling the Tumor

• Primary Goal: Complete en bloc surgical resection (R0) for cure.
• Core Strategy: Multimodal - Surgery + Post-Operative Radiotherapy (PORT).
• Surgical Approaches:
  • Craniofacial Resection (CFR): Gold standard for most; ensures wide margins.
  • Endoscopic Endonasal Approach (EEA): For selected, early-stage, central tumors.
• Radiotherapy (RT):
  • PORT: Standard, dose ~50-66 Gy. Improves local control.

  ⭐ PORT is crucial post-surgery, even with R0 resection, significantly boosting local control & survival, especially for advanced Kadish stages.

• Chemotherapy (CT):
  • Neoadjuvant (Cisplatin/Etoposide): For unresectable/bulky tumors to downstage.
  • Adjuvant/Palliative: For high-risk, recurrent, or metastatic disease.

Treatment Algorithm:

Future Focus - After the Fight

• Lifelong Surveillance: Essential due to high recurrence risk.
  • Regular clinical exams, nasal endoscopy.
  • Periodic MRI/CT scans (e.g., annually post 5 years).
• Recurrence:
  • Local: Salvage surgery, re-irradiation.
  • Regional/Distant: Systemic therapy.
• Prognosis: Depends on Kadish stage, Hyams grade, resection completeness.
  • 5-year survival: ~60-80% (limited), ↓ with advanced disease.
• Quality of Life: Manage olfactory loss, sinonasal symptoms.

⭐ Late recurrences (>5 years) are common, mandating indefinite surveillance.

High-Yield Points - ⚡ Biggest Takeaways

• Origin: Olfactory neuroepithelium (superior nasal cavity); presents with nasal obstruction, epistaxis.
• Bimodal age distribution: peaks at 10-20 years and 50-60 years.
• Hyams grading (histopathology) and Kadish staging (clinical) guide prognosis and treatment.
• Imaging: Classic "dumbbell" tumor via cribriform plate signifies intracranial spread.
• Histopathology: Homer Wright rosettes are a characteristic finding.
• Treatment: Craniofacial resection followed by adjuvant radiotherapy is standard.